Innovation and Start-Up Center for Biotechnology (IZB) welcomes consultancy KLIFO

Martinsried near Munich, 20. October 2022 – The Innovation and Start-up Center for Biotechnology (IZB), one of the leading biotechnology centers in Europe, and home to over 50 biotech start-ups, today announced that the Northern European consultancy KLIFO has moved into the IZB. KLIFO offers consulting and operational services in all areas of drug and medical device development and has more than 25 years of experience working with international companies in the biotech, pharmaceutical and medical device industries.

“IZB is the place to be for biotech start-ups,” said Dr Christoph Kapitza, Managing Director KLIFO. “Having a satellite office in IZB in addition to our existing office location in central Munich, enables us to be physically close to our clients. This is important to us, because we strive to build flexible and trust-based partnerships in which we work as an integrated part of the team.””We would like to welcome KLIFO to IZB. KLIFO’s expertise in drug and medical device development is a good fit for our biotechnology center and we are excited to see how the start-ups will leverage this knowledge and support,” added Dr Peter Hanns Zobel, Managing Director IZB.

KLIFO offers complete solutions for all areas of drug development, including strategic project management, regulatory affairs, clinical development, clinical trial supply, QA, CMC, non-clinical development and patient safety. In addition, KLIFO provides strategic advice as well as operational support in all these areas and works with clients on portfolio strategies, project development strategies and project execution.

With locations in Denmark, Germany, Sweden and the Netherlands and more than 200 highly qualified employees, all with extensive and longstanding industry experience, KLIFO’s team of experts supports its clients regardless of phase, scope or therapeutic area.

About the Innovation and Start-up Center for Biotechnology (IZB) in Martinsried near Munich
The Fördergesellschaft IZB mbH, founded in 1995, operates the Innovation and Start-up Centers for Biotechnology in Planegg-Martinsried and Freising-Weihenstephan and has developed into a leading biotechnology center. More than 50 biotech companies with over 700 employees are currently based on 26,000 m2. Here, work is being done on developing drugs for the most serious diseases, such as cancer, Alzheimer’s and various autoimmune diseases. A key criterion for the success of the IZBs is the physical proximity to cutting-edge research on the Martinsried/Grosshadern campus and the Weihenstephan campus. The new infrastructure measures such as the Faculty Club G2B (Gateway to Biotech), the IZB Residence CAMPUS AT HOME, the Elhardt chemistry college, the two kindergartens Bio Kids and Bio Kids2 as well as the two restaurants SEVEN AND MORE and THE BOWL Food Lounge are also location factors that are highly valued by the founders of the company. Successful companies that emerged from the IZB include Corimmun (today Janssen-Cilag), Coriolis, Exosome Diagnostics (bought by Bio-Techn), ibidi, Immunic Therapeutics, Medigene, Micromet (today Amgen), MorphoSys, Octopharma or Rigontec (now MSD). More information at www.izb-online.de

Press contact and image material requests
Susanne Simon, Head of Press and Public Relations
Innovation and Start-up Center for Biotechnology (IZB)
Am Klopferspitz 19, D-82152 Planegg-Martinsried, Tel.: +49 (0)89/55 279 48-17, Email: ed.enilno-bzi@nomis
Website: www.izb-online.de

About KLIFO
KLIFO is an integrated North-European drug and device development consultancy with significant experience in partnering with pharmaceutical, biotech and medtech companies. We enable our partners to maximise opportunity, mitigate risks, drive innovation and achieve efficient project advancement.
We offer end to end solutions across all drug development areas, including strategic project management, regulatory affairs, clinical development, clinical trial supply, quality assurance (QA), Chemistry Manufacturing and Controls (CMC) development, non-clinical development and pharmacovigilance in relation to the development of pharmaceutical products and medical devices. We provide strategic advice as well as operational support in all these areas, and we partner with clients on portfolio strategies, project development strategies and project execution.
KLIFO has offices in Denmark, Sweden, Germany and The Netherlands and employs more than 200 highly skilled employees. More information at www.klifo.com

Contact person KLIFO
Dr. Anthony Harris, Director Business Development Germany
Heimeranstraße 35, D-80339 München, Tel.: +49 (0) 151 6549 5755, Email: moc.ofilk@sirraH.ynohtnA
Website: www.klifo.com